Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
Adithya Hande, Head of Clinical Projects at DERBI Foundation, shared a post on LinkedIn:
”India’s Silent Killer — and a Scientific Breakthrough You Need to Know About
Thrombosis-related diseases (like pulmonary embolism, stroke, and DVT) are quietly responsible for millions of hospitalizations and deaths in India each year — especially post-COVID.
Yet, we’re still relying on decades-old anticoagulants with dangerous side effects like internal bleeding and poor patient adherence.
But what if we could prevent clots safely, without disrupting the body’s natural healing?
Scientists at IISc have developed a game-changing nanozyme that mimics antioxidant enzymes — a first-of-its-kind, bleeding-free clot therapy.
This article dives into:
- What makes this science revolutionary
- The current treatment challenges for thrombosis in India
- Market gaps ripe for startup innovation
- Why this could be a deeptech goldmine for healthcare entrepreneurs
Click below to read the full breakdown — from a healthcare innovation lens.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?